Construction Partners, Inc. Completes Georgia Acquisition
Company Expands into Columbus Metro Area DOTHAN, Ala., Aug. 1, 2024 /PRNewswire/ — Construction Partners, Inc. (NASDAQ: ROAD) (“CPI” or the “Company”),... Read more.
Cousins Properties and Town Lane Announce the Acquisition and Planned Modernization of Proscenium
ATLANTA, Aug. 1, 2024 /PRNewswire/ — Cousins Properties (NYSE: CUZ) and Town Lane announced today they have acquired Proscenium, a 526,000 square foot Class... Read more.
US LBM ACQUIRES SOUTH FLORIDA BUILDING PRODUCTS DISTRIBUTOR
National building materials distributor acquires L.D. Mullins Lumber Company RIVIERA BEACH, Fla., Aug. 1, 2024 /PRNewswire/ — US LBM, a leading distributor... Read more.
Rocket Companies Announces Second Quarter 2024 Results
Generated Q2’24 total revenue, net of $1.3 billion and adjusted revenue of $1.2 billion. Adjusted revenue exceeded the high end of guidance range and increased... Read more.
REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy... Read more.
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
– Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 – – Revumenib NDA in R/R KMT2Ar acute leukemia... Read more.
GoDaddy Reports Second Quarter 2024 Financial Results
Building on its track record of profitable growth, strong cash generation and share repurchases TEMPE, Ariz., Aug. 1, 2024 /PRNewswire/ — GoDaddy Inc. (NYSE:... Read more.
ARTHEx Biotech Announces Participation in Barclays Biotech: 1×1 Private Company Symposium
VALENCIA, Spain, Aug. 1, 2024 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through... Read more.
ICF Reports Second Quarter 2024 Results
— Favorable Business Mix and Higher Utilization Drove Strong EPS Performance — — Record Business Development Pipeline of $10.5 Billion at Quarter-End... Read more.
Congruence Therapeutics Announces Participation in Barclays Biotech: 1×1 Private Company Symposium
MONTREAL, Aug. 1, 2024 /PRNewswire/ — Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for... Read more.